These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 21907794

  • 1. Effect of counterions on the properties of amorphous atorvastatin salts.
    Sonje VM, Kumar L, Puri V, Kohli G, Kaushal AM, Bansal AK.
    Eur J Pharm Sci; 2011 Nov 20; 44(4):462-70. PubMed ID: 21907794
    [Abstract] [Full Text] [Related]

  • 2. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH, Gordon S, Holm R, Selen A, Rades T, Müllertz A.
    Eur J Pharm Biopharm; 2013 Nov 20; 85(3 Pt B):942-51. PubMed ID: 24075980
    [Abstract] [Full Text] [Related]

  • 3. An investigation into the influence of counterion on the properties of some amorphous organic salts.
    Towler CS, Li T, Wikström H, Remick DM, Sanchez-Felix MV, Taylor LS.
    Mol Pharm; 2008 Nov 20; 5(6):946-55. PubMed ID: 19434850
    [Abstract] [Full Text] [Related]

  • 4. Effect of counterion on the phase behaviour during lyophilization of indomethacin salt forms.
    Kumar L, Baheti A, Mokashi A, Bansal AK.
    Eur J Pharm Sci; 2011 Sep 18; 44(1-2):136-41. PubMed ID: 21767640
    [Abstract] [Full Text] [Related]

  • 5. Effect of a counterion on the glass transition temperature (T(g)') during lyophilization of ganciclovir salt forms.
    Kumar L, Baheti A, Bansal AK.
    Mol Pharm; 2011 Feb 07; 8(1):309-14. PubMed ID: 21133416
    [Abstract] [Full Text] [Related]

  • 6. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
    Caron V, Tajber L, Corrigan OI, Healy AM.
    Mol Pharm; 2011 Apr 04; 8(2):532-42. PubMed ID: 21323367
    [Abstract] [Full Text] [Related]

  • 7. Phase transformations undergone by Triton X-100 probed by differential scanning calorimetry and dielectric relaxation spectroscopy.
    Merino EG, Rodrigues C, Viciosa MT, Melo C, Sotomayor J, Dionísio M, Correia NT.
    J Phys Chem B; 2011 Nov 03; 115(43):12336-47. PubMed ID: 21928821
    [Abstract] [Full Text] [Related]

  • 8. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.
    Kim MS, Jin SJ, Kim JS, Park HJ, Song HS, Neubert RH, Hwang SJ.
    Eur J Pharm Biopharm; 2008 Jun 03; 69(2):454-65. PubMed ID: 18359211
    [Abstract] [Full Text] [Related]

  • 9. Phase behavior and oral bioavailability of amorphous Curcumin.
    Pawar YB, Shete G, Popat D, Bansal AK.
    Eur J Pharm Sci; 2012 Aug 30; 47(1):56-64. PubMed ID: 22609283
    [Abstract] [Full Text] [Related]

  • 10. Investigations on the effect of different cooling rates on the stability of amorphous indomethacin.
    Karmwar P, Boetker JP, Graeser KA, Strachan CJ, Rantanen J, Rades T.
    Eur J Pharm Sci; 2011 Oct 09; 44(3):341-50. PubMed ID: 21884789
    [Abstract] [Full Text] [Related]

  • 11. Crystal forms of atorvastatin.
    An SG, Sohn YT.
    Arch Pharm Res; 2009 Jun 09; 32(6):933-6. PubMed ID: 19557372
    [Abstract] [Full Text] [Related]

  • 12. Rheology and molecular mobility of amorphous blends of citric acid and paracetamol.
    Hoppu P, Hietala S, Schantz S, Juppo AM.
    Eur J Pharm Biopharm; 2009 Jan 09; 71(1):55-63. PubMed ID: 18656536
    [Abstract] [Full Text] [Related]

  • 13. Bulk, surface properties and water uptake mechanisms of salt/acid amorphous composite systems.
    Bianco S, Tewes F, Tajber L, Caron V, Corrigan OI, Healy AM.
    Int J Pharm; 2013 Nov 01; 456(1):143-52. PubMed ID: 23948137
    [Abstract] [Full Text] [Related]

  • 14. Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatin.
    Zhang F, Aaltonen J, Tian F, Saville DJ, Rades T.
    Eur J Pharm Biopharm; 2009 Jan 01; 71(1):64-70. PubMed ID: 18703139
    [Abstract] [Full Text] [Related]

  • 15. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.
    Löbmann K, Laitinen R, Grohganz H, Gordon KC, Strachan C, Rades T.
    Mol Pharm; 2011 Oct 03; 8(5):1919-28. PubMed ID: 21815614
    [Abstract] [Full Text] [Related]

  • 16. Correlating thermodynamic and kinetic parameters with amorphous stability.
    Graeser KA, Patterson JE, Zeitler JA, Gordon KC, Rades T.
    Eur J Pharm Sci; 2009 Jun 28; 37(3-4):492-8. PubMed ID: 19394421
    [Abstract] [Full Text] [Related]

  • 17. Effect of amorphization method on telmisartan solubility and the tableting process.
    Lepek P, Sawicki W, Wlodarski K, Wojnarowska Z, Paluch M, Guzik L.
    Eur J Pharm Biopharm; 2013 Jan 28; 83(1):114-21. PubMed ID: 23085331
    [Abstract] [Full Text] [Related]

  • 18. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process.
    Kim JS, Kim MS, Park HJ, Jin SJ, Lee S, Hwang SJ.
    Int J Pharm; 2008 Jul 09; 359(1-2):211-9. PubMed ID: 18501538
    [Abstract] [Full Text] [Related]

  • 19. Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.
    Kasten G, Nouri K, Grohganz H, Rades T, Löbmann K.
    Int J Pharm; 2017 Nov 25; 533(1):138-144. PubMed ID: 28947246
    [Abstract] [Full Text] [Related]

  • 20. Early drug development predictions of glass-forming ability and physical stability of drugs.
    Mahlin D, Bergström CA.
    Eur J Pharm Sci; 2013 May 13; 49(2):323-32. PubMed ID: 23557841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.